8P Genomic variants associated with interstitial lung disease in patients treated with trastuzumab-deruxtecan: Results from the PROCURE project
Rodrigo Sánchez-Bayona(Hospital Universitario 12 De Octubre), Johny Nicolas(Instituto de Investigaciones Biomédicas Sols-Morreale), C. Saura Manich(Vall d'Hebron Hospital Universitari), M. Gion Cortes(Hospital Universitario Ramón y Cajal), Juan Miguel Cejalvo(Hospital Clínico Universitario de Valencia), E. Llabrés Valentí(Hospital Universitario Insular de Gran Canaria), J. Cortés, A. Falcon Gonzalez(Hospital Universitario Virgen del Rocío), S. Pernas Simon(Institut Català d'Oncologia), A. López de Sá(Hospital Clínico San Carlos), M.J. Vidal Losada(Hospital Clínic de Barcelona), C. Hinojo González(Marqués de Valdecilla University Hospital), Tyler J. Curiel(Complejo Hospitalario Universitario de Santiago), J. Cruz Jurado(Hospital Universitario de Canarias), María José Echarri(Hospital Universitario Severo Ochoa), María Isabel Gallegos Sancho(MD Anderson Cancer Center Madrid), Alberto M. Arenas(Instituto de Investigaciones Biomédicas Sols-Morreale), Guillermo Villacampa(Solti), E.M. Ciruelos(Hospital Universitario 12 De Octubre), Cristina Rodríguez‐Antona(Instituto de Investigaciones Biomédicas Sols-Morreale)
Cited by 0Open Access
Abstract
Trastuzumab-deruxtecan (T-DXd) has demonstrated remarkable results in advanced breast cancer. However, 10-15% of treated patients develop interstitial lung disease (ILD), which is a frequent cause of treatment discontinuation. Potential germline markers in ILD susceptibility remain unexplored.
Related Papers
No related papers found
Powered by citation graph analysis